mardi 2 juin 2015

Onco Actu "Spécial ASCO" du 2 juin 2015

5.5 ASCO

First Version of CancerLinQ™ Data Analytics Platform Debuts at 51st ASCO Annual Meeting [ASCO]

5.5.1 ASCO (général)

Beware the hype over 'miracle' cancer drugs [The Telegraph] ASCO (général) - Industriels

ASCO 15: The top 10 setbacks, advances and head scratchers [FierceBiotech]

Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types [Merck]

ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab [TheStreet]

5.5.10 ASCO (hémato)

Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia [Gilead]

Juno amps up its CAR-T tech in drive toward a pivotal test [FierceBiotech]

Juno's Investigational CAR T Cell Product Candidate JCAR014 Demonstrates Encouraging Clinical Responses and Translational Insights in Patients With B-Cell Cancers [Juno]

Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma [Novartis]

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia [Johnson & Johnson]

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients [Johnson & Johnson]

Novartis, Juno Killer T-Cells Show Promise In Another Blood Cancer [Forbes]

5.5.12 ASCO (médico-éco)

Anthem Plan for Containing Cancer Drug Costs Shows Promising Signs [Wall Street Journal]

Top Oncologist To Convention Of Doctors, Pharma Execs: New Cancer Treatments Cost Too Damn Much [Forbes]

5.5.13 ASCO (divers)

Cancer trials aim to shore up 'precision medicine's' base of evidence [LA Times]

U.S. Cancer Study to Match Existing Drugs to Genetic Mutations [Wall Street Journal]

NCI-MATCH Trial Links Targeted Drugs to Mutations [National Cancer Institute]

ASCO Launches First-ever Clinical Trial: Aims to Learn from Patients with Advanced Cancer Who Lack Standard Treatment Options [ASCO]

Oncotype DX® Presentations at ASCO in Breast and Prostate Cancer Reinforce Genomic Health's Leadership in Optimizing Cancer Treatment [Genomic Health]

Tests for new cancer drugs not reliable enough, doctors say [Reuters]

Transition to gene-based cancer treatment may not be simple [Reuters]

Cancer trials aim to shore up 'precision medicine's' base of evidence [LA Times]

Tests for new cancer drugs not reliable enough, doctors say [Reuters]

Large U.S. cancer trial to match genetic glitches to targeted drugs [Reuters]

ASCO Presenter Touts Comparative Genomics with Dog, Sea Lion Models as Source of Cancer Clues [Genome Web]

5.5.2 ASCO (sein)

Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival [Puma]

New Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 American Society of Clinical Oncology Annual Meeting [Astellas]

Puma Bio Breast Cancer Drug Given Rough Treatment at ASCO '15 [TheStreet]

'Amazing' new breast cancer drugs could extend life of sufferers [TheTelegraph]

Taking extra breast tissue halves need for second cancer surgery [Reuters]

5.5.3 ASCO (prostate)

OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis [OncoGenex]

5.5.4 ASCO (immunothérapies)

Immunotherapy drugs show continued promise [Cancer Research UK]

Immunotherapy: the big new hope for cancer treatment [The Guardian]

5.5.5 ASCO (gastro-intestinal)

Radioactive particles combined with chemotherapy slow advanced bowel cancer growth in the liver [Cancer Research UK]

5.5.6 ASCO (peau)

Immunotherapy drug combo could combat melanoma [NHS Choices]

Cancer patient's tumours disappeared with groundbreaking treatment [The Telegraph]

5.5.8 ASCO (poumon)

Foundation Medicine Identifies Patients Likely to Respond to Certain MET Inhibitor Targeted Therapies; Durable Responses in Non-Small Cell Lung Cancer (NSCLC) Presented at ASCO Annual Meeting [Foundation Medicine]

ARIAD Presents Updated Clinical Data on brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer at the 2015 ASCO Meeting [ARIAD]

Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs [Novartis]

AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting [AbbVie]

5.5.9 ASCO (autres organes)

OncoGenex Announces Data from Borealis-1™ Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer [OncoGenex]